Halomine
1 known investors
AvantGuard develops Avantamine, an antimicrobial molecule that eliminates bacteria, viruses, and fungi on surfaces and skin without generating resistance, with an initial focus on topical treatment of the drug-resistant fungal pathogen Candida auris. The technology can be formulated as an antiseptic, disinfectant, surface coating, or plastics additive for use in healthcare settings.
Investors · 1
Non-dilutive funding · 9 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $325K |
| Department of Agriculture (USDA) | Phase I | 2022 | $175K |
| National Science Foundation | Phase II | 2021 | $1M |
| Department of Agriculture (USDA) | Phase II | 2020 | $600K |
| National Science Foundation | Phase I | 2020 | $256K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $250.3K |
| National Science Foundation | Phase I | 2020 | $225K |
| U.S. ArmyArmy | Phase I | 2020 | $99.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.